Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to compare the effectiveness of commonly used immunosuppressant treatments for early diffuse cutaneous systemic sclerosis (SSc).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Manchester
• Treatments: Cyclophosphamide; Immunosuppressive Agents; Methotrexate; Mycophenolate mofetil; Mycophenolic Acid

Criteria

Inclusion Criteria:

Age > 18 Skin thickening < 3 years Immunosuppressant use < 4 months Proximal skin involvement to face/neck, elbow or knee

Exclusion Criteria:

Previous use of more than 4 months of methotrexate, mycophenolate mofetil, cyclophosphamide or other immunosuppressive treatments

Previous use of immunosuppressant therapy other than methotrexate, mycophenolate mofetil or cyclophosphamide within previous months

Previous stem cell transplantation therapy